Thus, we explored functional effects of both IFN-λ3 and IFN-λ4 in a panel of hepatoma HepG2 cell lines, in which we inducibly expressed IFN-λ3-GFP or IFN-λ4-GFP and used CRISPR-Cas9 gene editing to eliminate IFNLR1, the receptor used by all type III IFNs (Figure S1). Here, IFNL4 is linked to hepatocellular carcinoma.